Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Urol Oncol. 2024 Dec;42(12):453.e15-453.e22. doi: 10.1016/j.urolonc.2024.09.012. Epub 2024 Oct 5.
This study aimed to compare the clinical outcomes of robot-assisted partial nephrectomy (RAPN) and image-guided percutaneous cryoablation (IG-PCA) for clinical T1 renal cell carcinoma.
We conducted a retrospective analysis of 679 patients with clinical T1 renal cell carcinoma treated with RAPN or IG-PCA between 2012 and 2021. Propensity scores were calculated via logistic analysis to adjust for imbalances in baseline characteristics. We compared oncological and functional outcomes between the 2 treatment groups.
Following the matching process, 108 patients were included in each group. No patient in the RAPN group developed local recurrence. In the IG-PCA group, three patients experienced local tumor progression. The patients underwent salvage thermal ablations by the secondary technique; 2 underwent IG-PCA and 1 underwent microwave ablation, resulting in a local control rate of 100%. The Kaplan-Meier analysis showed no statistically significant differences between the groups in terms of 5-year recurrence-free survival, metastasis-free survival, and overall survival (log-rank test; P = 0.11, P = 0.64, and P = 0.17, respectively). No significant differences were observed in the 2 treatments in major and overall complication rates (P = 0.75 and P = 0.82, respectively). Both groups showed similar rates of less than 10% estimated glomerular filtration rate decline at 12 months post-treatment and 5-year renal function preservation rates (P = 0.88 and P = 0.38, respectively).
IG-PCA demonstrated oncological outcomes comparable to those of RAPN. RAPN addressed the disadvantages of conventional procedures and allowed for safety outcomes comparable to IG-PCA.
本研究旨在比较机器人辅助部分肾切除术(RAPN)和影像引导经皮冷冻消融术(IG-PCA)治疗临床 T1 期肾细胞癌的临床疗效。
我们对 2012 年至 2021 年间接受 RAPN 或 IG-PCA 治疗的 679 例临床 T1 期肾细胞癌患者进行了回顾性分析。采用逻辑分析计算倾向评分,以调整基线特征的不平衡。我们比较了两组患者的肿瘤学和功能结局。
在匹配过程后,每组纳入 108 例患者。RAPN 组无患者发生局部复发。IG-PCA 组有 3 例患者发生局部肿瘤进展。这些患者采用辅助技术进行了挽救性热消融治疗;2 例患者接受 IG-PCA,1 例患者接受微波消融,局部控制率达到 100%。Kaplan-Meier 分析显示,两组患者在 5 年无复发生存率、无转移生存率和总生存率方面无统计学差异(log-rank 检验;P=0.11、P=0.64 和 P=0.17)。两种治疗方法在主要并发症和总并发症发生率方面无显著差异(P=0.75 和 P=0.82)。两组患者在 12 个月时肾小球滤过率下降小于 10%的比例和 5 年肾功能保留率方面相似(P=0.88 和 P=0.38)。
IG-PCA 显示出与 RAPN 相当的肿瘤学疗效。RAPN 解决了传统手术的缺点,并且安全性结果与 IG-PCA 相当。